Germany's Merck suffers setback with cancer drug

BERLIN (AP) — German pharmaceutical company Merck KgaA says a late stage trial of a new lung cancer drug has failed to meet expectations.

The company, based in Darmstadt, says the drug Stimuvax did not improve the overall survival of patients in the phase III study.

Merck shares fell 3.1 percent to €98.20 ($129.41) after the announcement early Wednesday.

The company is a separate entity from Merck & Co., which is based in the U.S.

Associated Press
Copyright 2012 The Associated Press. All rights reserved. This material may not be published, broadcast, rewritten or redistributed.


Join the Conversation!

While WVLT allows comments on articles, we ask that you respect the online community. Comments may be removed at any time for violations including:

  • Obscenity, profanity, vulgarity, racism, violent descriptions, name-calling or personal attacks.
  • Abuse of multiple accounts.
  • Off-topic comments.

Comments may be checked for inappropriate content or rule violation, but the station is under no legal obligation to monitor or remove comments. If you believe a comment violates the above rules, please use the Flagging Tool to alert a Moderator. 
Flagging does not guarantee removal.

powered by Disqus

WVLT VOLUNTEER TV

6450 Papermill Drive Knoxville, TN 37919 Phone - (865) 450-8888; Fax - (865) 450-8869
Copyright © 2014 WVLT-TV Inc. - Designed by Gray Digital Media - Powered by Clickability 184242591 - local8now.com/a?a=184242591
Gray Television, Inc.